Values First Advisors Inc. Buys Shares of 1,315 Blueprint Medicines Co. (NASDAQ:BPMC)

Values First Advisors Inc. purchased a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) in the third quarter, Holdings Channel.com reports. The institutional investor purchased 1,315 shares of the biotechnology company’s stock, valued at approximately $122,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Triad Wealth Partners LLC bought a new stake in shares of Blueprint Medicines in the 2nd quarter worth about $27,000. Covestor Ltd increased its holdings in Blueprint Medicines by 9,700.0% in the first quarter. Covestor Ltd now owns 294 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 291 shares during the last quarter. Headlands Technologies LLC lifted its holdings in Blueprint Medicines by 105.2% during the 1st quarter. Headlands Technologies LLC now owns 667 shares of the biotechnology company’s stock worth $63,000 after buying an additional 342 shares during the last quarter. Natixis bought a new position in Blueprint Medicines during the 1st quarter worth approximately $73,000. Finally, CWM LLC grew its position in shares of Blueprint Medicines by 114.6% in the 2nd quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after acquiring an additional 590 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts recently issued reports on BPMC shares. UBS Group started coverage on Blueprint Medicines in a research note on Thursday. They set a “neutral” rating and a $88.00 price objective on the stock. Guggenheim boosted their price objective on shares of Blueprint Medicines from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Morgan Stanley raised their target price on shares of Blueprint Medicines from $110.00 to $115.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. Robert W. Baird lifted their target price on Blueprint Medicines from $112.00 to $127.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Oppenheimer increased their price target on Blueprint Medicines from $114.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, July 8th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $118.22.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $82.47 on Friday. Blueprint Medicines Co. has a 12-month low of $47.66 and a 12-month high of $121.90. The stock has a market capitalization of $5.16 billion, a P/E ratio of -17.15 and a beta of 0.58. The firm’s 50 day moving average is $89.55 and its 200-day moving average is $98.49. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.65.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.49. The business had revenue of $138.20 million for the quarter, compared to analysts’ expectations of $104.02 million. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The company’s quarterly revenue was up 139.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.19) EPS. Equities research analysts anticipate that Blueprint Medicines Co. will post -3.99 EPS for the current fiscal year.

Insider Transactions at Blueprint Medicines

In related news, insider Philina Lee sold 41,913 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $93.19, for a total value of $3,905,872.47. Following the completion of the sale, the insider now owns 34,729 shares in the company, valued at approximately $3,236,395.51. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Philina Lee sold 41,913 shares of the company’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the transaction, the insider now directly owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Fouad Namouni sold 3,633 shares of the stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total value of $324,499.56. Following the completion of the sale, the insider now directly owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.21% of the stock is currently owned by insiders.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.